Policy Makers

This document outlines the United States Government's global TB strategy.

This report presents summary data for U.S. TB cases reported to the Division of TB Elimination, CDC, during 2014.

This infographic was adapted from the CDC Division of Tuberculosis Elimination’s Take on TB infographic. Staff at the New Mexico Department of Health adapted the resource to include statistics specific to their state. Additional information, such as the cost to treat latent TB infection, was also added.

This is the 20th global report on tuberculosis (TB) published by WHO in a series that started in 1997. It provides a comprehensive and up-to-date assessment of the TB epidemic and progress in implementing and financing TB prevention, care and control at global, regional and country levels using data reported by 200 countries and territories that account for over 99% of the world’s TB cases.

This document highlights strategic directions to integrate digital health into TB prevention and care activities in support of WHO’s End TB Strategy.

This document is the first language guide for partners and stakeholders working in tuberculosis.These recommendations have been developed for use by everyone involved in the fight against TB and are aimed at reducing stigmatizing TB language.

This plan is based on the End TB strategy. Specifically it speaks about preventing TB, active case finding and contact tracing, focusing attention to key vulnerable and marginalized groups, development and roll out of new tools, and implementing TB services packages that are comprehensive and work in different types of epidemic and socioeconomic environments.

This document shares best practices in engagement of health care providers in programmatic management of drug-resistant tuberculosis that have been documented in different countries and regions and implemented by different stakeholders. Case studies presented in the document are lessons learned for scale-up of public-private mix for the management of drug-resistant TB at country level.

This document is a compilation of survivor stories that feature the personal journeys of 15 individuals who have fought against TB disease.

This report analyses the factors affecting access to treatment regimens for drug-resistant tuberculosis (DR-TB), including new and repurposed drugs. Detailed pricing profiles of key DR-TB drugs are also provided.